X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs IPCA LABS - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD IPCA LABS ORCHID PHARMA LTD/
IPCA LABS
 
P/E (TTM) x -0.2 29.7 - View Chart
P/BV x 0.2 3.5 4.5% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ORCHID PHARMA LTD   IPCA LABS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
IPCA LABS
Mar-18
ORCHID PHARMA LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs194695 27.9%   
Low Rs35400 8.8%   
Sales per share (Unadj.) Rs276.5260.2 106.3%  
Earnings per share (Unadj.) Rs-79.219.0 -417.5%  
Cash flow per share (Unadj.) Rs-43.533.1 -131.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9213.0 25.3%  
Shares outstanding (eoy) m70.45126.20 55.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.1 19.7%   
Avg P/E ratio x-1.428.9 -5.0%  
P/CF ratio (eoy) x-2.616.6 -15.9%  
Price / Book Value ratio x2.12.6 82.6%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m8,06769,120 11.7%   
No. of employees `0002.813.3 21.1%   
Total wages/salary Rs m2,5277,359 34.3%   
Avg. sales/employee Rs Th6,956.12,477.4 280.8%   
Avg. wages/employee Rs Th902.5555.2 162.6%   
Avg. net profit/employee Rs Th-1,993.0180.6 -1,103.3%   
INCOME DATA
Net Sales Rs m19,47732,836 59.3%  
Other income Rs m407418 97.4%   
Total revenues Rs m19,88433,254 59.8%   
Gross profit Rs m1,1034,505 24.5%  
Depreciation Rs m2,5191,777 141.7%   
Interest Rs m5,227240 2,176.0%   
Profit before tax Rs m-6,2362,905 -214.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125511 -24.5%   
Profit after tax Rs m-5,5802,394 -233.1%  
Gross profit margin %5.713.7 41.3%  
Effective tax rate %2.017.6 11.4%   
Net profit margin %-28.77.3 -392.9%  
BALANCE SHEET DATA
Current assets Rs m11,01419,455 56.6%   
Current liabilities Rs m32,06010,076 318.2%   
Net working cap to sales %-108.128.6 -378.3%  
Current ratio x0.31.9 17.8%  
Inventory Days Days9598 96.9%  
Debtors Days Days3467 50.1%  
Net fixed assets Rs m29,44020,260 145.3%   
Share capital Rs m705252 279.1%   
"Free" reserves Rs m2,04326,633 7.7%   
Net worth Rs m3,80026,886 14.1%   
Long term debt Rs m9,0182,340 385.4%   
Total assets Rs m46,51041,173 113.0%  
Interest coverage x-0.213.1 -1.5%   
Debt to equity ratio x2.40.1 2,726.6%  
Sales to assets ratio x0.40.8 52.5%   
Return on assets %-0.86.4 -11.9%  
Return on equity %-146.98.9 -1,649.1%  
Return on capital %-3.710.8 -34.7%  
Exports to sales %37.947.6 79.5%   
Imports to sales %22.614.9 152.1%   
Exports (fob) Rs m7,37815,642 47.2%   
Imports (cif) Rs m4,4064,884 90.2%   
Fx inflow Rs m7,51315,642 48.0%   
Fx outflow Rs m5,6494,884 115.7%   
Net fx Rs m1,86510,759 17.3%   
CASH FLOW
From Operations Rs m1,6823,411 49.3%  
From Investments Rs m-9,860-1,354 728.2%  
From Financial Activity Rs m6,644-1,304 -509.5%  
Net Cashflow Rs m-1,535753 -203.8%  

Share Holding

Indian Promoters % 32.3 45.9 70.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.4 40.4%  
FIIs % 3.3 25.3 13.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.4 317.8%  
Shareholders   84,811 36,892 229.9%  
Pledged promoter(s) holding % 54.9 2.1 2,566.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS